Patents by Inventor Philip Kantoff

Philip Kantoff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220042105
    Abstract: The present invention provides methods of screening for and diagnosing prostate cancer and methods of choosing a therapeutic for prostate cancer based on using KDM5D expression level to identify which patients with hormone sensitive prostate cancer benefit from primary castration and taxane and who with castration resistant prostate cancer would benefit from docetaxel plus an androgen receptor antagonists added to the ongoing castration. The disclosure also provides methods of screening for and diagnosing prostate cancer and methods of choosing a therapeutic for prostate cancer based on a lower KDM5D expression having a more aggressive clinical course of prostate cancer in human patients.
    Type: Application
    Filed: June 17, 2021
    Publication date: February 10, 2022
    Inventors: CHRISTOPHER SWEENEY, PHILIP KANTOFF, GWO-SHU MARY LEE, KAZUMASA KOMURA
  • Patent number: 11066708
    Abstract: The present invention provides methods of screening for and diagnosing prostate cancer and methods of choosing a therapeutic for prostate cancer based on using KDM5D expression level to identify which patients with hormone sensitive prostate cancer benefit from primary castration and taxane and who with castration resistant prostate cancer would benefit from docetaxel plus an androgen receptor antagonists added to the ongoing castration. The disclosure also provides methods of screening for and diagnosing prostate cancer and methods of choosing a therapeutic for prostate cancer based on a lower KDM5D expression having a more aggressive clinical course of prostate cancer in human patients.
    Type: Grant
    Filed: December 30, 2016
    Date of Patent: July 20, 2021
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Christopher Sweeney, Philip Kantoff, Gwo-Shu Mary Lee, Kazumasa Komura
  • Publication number: 20190024185
    Abstract: The present invention provides methods of screening for and diagnosing prostate cancer and methods of choosing a therapeutic for prostate cancer based on using KDM5D expression level to identify which patients with hormone sensitive prostate cancer benefit from primary castration and taxane and who with castration resistant prostate cancer would benefit from docetaxel plus an androgen receptor antagonists added to the ongoing castration. The disclosure also provides methods of screening for and diagnosing prostate cancer and methods of choosing a therapeutic for prostate cancer based on a lower KDM5D expression having a more aggressive clinical course of prostate cancer in human patients.
    Type: Application
    Filed: December 30, 2016
    Publication date: January 24, 2019
    Inventors: CHRISTOPHER SWEENEY, PHILIP KANTOFF, GWO-SHU MARY LEE, KAZUMASA KOMURA
  • Publication number: 20180135132
    Abstract: Diagnostic assays for medically classifying cancer patients are provided. The method comprises assessing a tissue sample of the patient for the presence of a copy number gain of chromosome regions 1q23.3 and/or 1q21.2. Copy number gain of chromosome regions 1q23.3 and/or 1q21.2 is indicative of a less favorable prognosis as compared to the prognosis if there was no copy number gain in the same regions.
    Type: Application
    Filed: October 24, 2017
    Publication date: May 17, 2018
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Jonathan E. Rosenberg, Joaquim Bellmunt, Philip Kantoff, Massimo Loda
  • Patent number: 9828643
    Abstract: Diagnostic assays for medically classifying cancer patients are provided. The method comprises assessing a tissue sample of the patient for the presence of a copy number gain of chromosome regions 1q23.3 and/or 1q21.2. Copy number gain of chromosome regions 1q23.3 and/or 1q21.2 is indicative of a less favorable prognosis as compared to the prognosis if there was no copy number gain in the same regions.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: November 28, 2017
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Jonathan E. Rosenberg, Joaquim Bellmunt, Philip Kantoff, Massimo Loda
  • Publication number: 20130165331
    Abstract: Diagnostic assays for medically classifying cancer patients are provided. The method comprises assessing a tissue sample of the patient for the presence of a copy number gain of chromosome regions 1q23.3 and/or 1q21.2. Copy number gain of chromosome regions 1q23.3 and/or 1q21.2 is indicative of a less favorable prognosis as compared to the prognosis if there was no copy number gain in the same regions.
    Type: Application
    Filed: May 18, 2012
    Publication date: June 27, 2013
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Jonathan E. Rosenberg, Joaquim Bellmunt, Philip Kantoff, Massimo Loda
  • Publication number: 20120295807
    Abstract: Diagnostic assays for medically classifying cancer patients are provided. The method comprises assessing a tissue sample of the patient for the presence of a copy number gain of chromosome regions 1q23.3 and/or 1q21.2. Copy number gain of chromosome regions 1q23.3 and/or 1q21.2 is indicative of a less favorable prognosis as compared to the prognosis if there was no copy number gain in the same regions.
    Type: Application
    Filed: May 18, 2012
    Publication date: November 22, 2012
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Jonathan E. Rosenberg, Joaquim Bellmunt, Philip Kantoff, Massimo Loda